Collaborative Drug Discovery expanded its AI collaboration with Eli Lilly by planning tighter integration of Lilly TuneLab predictive models into CDD Vault workflows. The agreement targets ADMET modeling inside CDD Vault and sets up broader model integration across the platform’s core and AI modules for participating biopharma companies. CDD framed the partnership as an extension of its web-based collaboration approach, enabling secure access to Lilly’s proprietary-trained models while keeping analysis and experimentation inside a protected environment. The companies said the models are designed to fit naturally into experimental and computational workflows. The move underscores how major pharma is turning internal AI assets into partner-facing toolkits, as biotechs look to accelerate target and lead optimization using curated, high-quality predictive models.